Ignite Creation Date:
2024-05-06 @ 3:10 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02226757
Status:
UNKNOWN
Last Update Posted:
2014-08-27
First Post:
2014-06-02
Brief Title:
Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients
Sponsor:
Amsterdam UMC location VUmc
Organization:
Amsterdam UMC location VUmc
Study Overview
Official Title:
Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment a Pilot-study
Status:
UNKNOWN
Status Verified Date:
2014-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs Tumor biopsies will be evaluated for HER2-expression In case of HER2 expression patients can participate in the trial after obtaining informed consent
Patients will be treated with weekly paclitaxel-trastuzumab
Patients will be treated with weekly paclitaxel-trastuzumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None